Literature DB >> 24319205

Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Deepa Manwani1, Paul S Frenette.   

Abstract

Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24319205     DOI： 10.1182/asheducation-2013.1.362

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  19 in total

1.  Assessment of perfused foveal microvascular density and identification of nonperfused capillaries in healthy and vasculopathic eyes.

Authors:  Alexander Pinhas; Moataz Razeen; Michael Dubow; Alexander Gan; Toco Y Chui; Nishit Shah; Mitul Mehta; Ronald C Gentile; Rishard Weitz; Joseph B Walsh; Yusufu N Sulai; Joseph Carroll; Alfredo Dubra; Richard B Rosen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-20       Impact factor: 4.799

Review 2.  New insights into the pathophysiology and development of novel therapies for sickle cell disease.

Authors:  Scott Moerdler; Deepa Manwani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Anemia: progress in molecular mechanisms and therapies.

Authors:  Vijay G Sankaran; Mitchell J Weiss
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

Review 4.  Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.

Authors:  Joep W R Sins; David J Mager; Shyrin C A T Davis; Bart J Biemond; Karin Fijnvandraat
Journal:  Blood Adv       Date:  2017-08-22

5.  Circulating fibrocytes as biomarkers of impaired lung function in adults with sickle cell disease.

Authors:  Borna Mehrad; Marie D Burdick; Nancy J Wandersee; Kaushik S Shahir; Liyun Zhang; Pippa M Simpson; Robert M Strieter; Joshua J Field
Journal:  Blood Adv       Date:  2017-11-06

Review 6.  Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.

Authors:  Varun Sagi; Donovan A Argueta; Stacy Kiven; Kalpna Gupta
Journal:  Complement Ther Med       Date:  2020-05-11       Impact factor: 2.446

7.  Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.

Authors:  Jon A Detterich; Honglei Liu; Silvie Suriany; Roberta M Kato; Patjanaporn Chalacheva; Bruke Tedla; Payal M Shah; Michael C Khoo; John C Wood; Thomas D Coates; Ginger L Milne; Joo-Yeun Oh; Rakesh P Patel; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2019-07-03       Impact factor: 7.376

Review 8.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

9.  Red Blood Cell Adhesion to Heme-Activated Endothelial Cells Reflects Clinical Phenotype in Sickle Cell Disease.

Authors:  Erdem Kucukal; Anton Ilich; Nigel S Key; Jane A Little; Umut A Gurkan
Journal:  Am J Hematol       Date:  2018-06-15       Impact factor: 10.047

10.  Updated Mechanisms of Sickle Cell Disease-Associated Chronic pain.

Authors:  Brianna Lutz; Steffen E Meiler; Alex Bekker; Yuan-Xiang Tao
Journal:  Transl Perioper Pain Med       Date:  2015-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.